CRT 2023
ACS & AMI Management
Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI
Professor of Medicine (Cardiology), and Population Health Science and Policy; Director of Interventional Cardiovascular Research and Clinical Trials
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Disclosure(s): Abbot, abiomed, alleviant medical, amgen, am-pharma, arena, AstraZeneca, Atricure: Grant/Research Support (Ongoing); Applied Therapeutics, Elixir Medical, Stel, ControlRad (spouse): Stock-privately held company (Ongoing); Bayer, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CeloNova, Chiesi: Grant/Research Support (Ongoing); Cine-Med Research, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Vectura, WebMD: Consultant (Ongoing); Concept Medical, CSL Behring, Cytosorbents, Daiichi Sankyo, Element Science, Faraday, Filterlex Medical, Humacyte, Idorsia Pharmaceuticals, Janssen, Mediasphere, Medtelligence: Grant/Research Support (Ongoing); Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll: Grant/Research Support (Ongoing); Scientific Advisory Board for AMA, ACC (BOT Member, SC Member CTR Program), SCAI (Women in Innovations Committee Member), JAMA Cardiology Associate Editor; Faculty CRF: Scientific Advisory Board (Ongoing)